Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer

	Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer
	He, Dongfeng 1; Ma, Lihong 2; Feng, Rennan 3; Zhang, Liangcai 4,5; Jiang, Yongshuai 5; Zhang, Yanqiao 6; Liu, Guiyou 7
刊名	BIOMEDICINE & PHARMACOTHERAPY
	2015-08-01
卷号	74 页码:164-168
关键词	Genome-wide association studies Colorectal cancer rs10411210 Meta-analysis
英文摘要	Colorectal cancer (CRC) is the third most common form of cancer and the second leading cause of cancer-related death in the Western countries. In order to detect common CRC genetic variants, genome-wide association studies (GWAS) have been performed and reported some novel CRC susceptibility variants. RHPN2 is located on 9q13.11, which encodes a member of the rhophilin family of Ras-homologous (Rho)GTPase binding proteins. RHPN2 gene rs10411210 polymorphism was identified to be significantly associated with CRC in European ancestry. GWAS and candidate studies investigate whether rs10411210 polymorphism is associated with CRC risk in European, Asian and American populations. However, most studies reported no association. Evidence shows that RHPN2 rs10411210 variant may be a prognostic biomarker for patients with surgically resected CRC. Here we reevaluated this association using large-scale samples from 15 studies (131580 samples including 53564 CRC cases and 78016 controls) using meta-analysis method by searching the PubMed and Google Scholar databases. We did not identify significant heterogeneity among these 15 studies (P = 0.4201 and I-2 = 2.8%). Our results showed significant association between rs10411210 and CRC (P = 9.17E-14, odds ratio (OR) = 1.10, 95% confidence interval (CI) 1.07-1.13). In subgroup analysis, we found significant association between rs10411210 and CRC in European population with P = 5.70E-09, OR = 1.14, 95% CI 1.10-1.20 and Asian population with P = 3.36E-07, OR = 1.11, 95% CI 1.07-1.16, but not American population with P = 0.0576, OR = 1.05, 95% CI 1.00-1.09. Collectively, our analysis further highlights significant association between rs10411210 polymorphism and colorectal cancer. (C) 2015 Elsevier Masson SAS. All rights reserved.
WOS标题词	Science & Technology ; Life Sciences & Biomedicine
类目[WOS]	Medicine, Research & Experimental ; Pharmacology & Pharmacy
研究领域[WOS]	Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]	GENOME-WIDE ASSOCIATION ; SUSCEPTIBILITY LOCI ; RISK LOCI ; CHINESE POPULATION ; GENETIC-VARIANTS ; FUNNEL PLOTS ; METAANALYSIS ; BIAS ; AMERICANS ; AFRICAN
收录类别	SCI
语种	英语
WOS记录号	WOS:000361182600025
内容类型	期刊论文
源URL	[http://124.16.173.210/handle/834782/1572]
专题	天津工业生物技术研究所_基因组分析实验室陈祖耕_期刊论文
作者单位	1.Harbin Med Univ, Dept Intervent, Affliated Tumor Hosp, Harbin 150040, Heilongjiang, Peoples R China 2.Harbin Med Univ, Comprehens Internal Med Therapy Area, Affliated Tumor Hosp, Harbin 150040, Heilongjiang, Peoples R China 3.Harbin Med Univ, Dept Nutr & Food Hyg, Sch Publ Hlth, Harbin 150040, Heilongjiang, Peoples R China 4.Rice Univ, Dept Stat, Houston, TX 77251 USA 5.Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150040, Heilongjiang, Peoples R China 6.Harbin Med Univ, Dept Gastrointestinal Med Oncol, Affiliated Tumor, Harbin 150040, Heilongjiang, Peoples R China 7.Chinese Acad Sci, Tianjin Inst Ind Biotechnol, Genome Anal Lab, Tianjin 300308, Peoples R China
推荐引用方式 GB/T 7714	He, Dongfeng,Ma, Lihong,Feng, Rennan,et al. Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer[J]. BIOMEDICINE & PHARMACOTHERAPY,2015,74:164-168.
APA	He, Dongfeng.,Ma, Lihong.,Feng, Rennan.,Zhang, Liangcai.,Jiang, Yongshuai.,...&Liu, Guiyou.(2015).Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer.BIOMEDICINE & PHARMACOTHERAPY,74,164-168.
MLA	He, Dongfeng,et al."Analyzing large-scale samples highlights significant association between rs10411210 polymorphism and colorectal cancer".BIOMEDICINE & PHARMACOTHERAPY 74(2015):164-168.